RxDoctor Payments Data

Marcus Witzel

Psychiatric/Mental Health · Cullman, ALNPI 1265177661

Payments from drug & device makers

$2,462in general payments, 2019–2025

Across 129 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$769
  • Otsuka America Pharmaceutical, Inc.$315
  • AbbVie$270
  • Teva Pharmaceuticals USA, Inc.$268
  • Takeda Pharmaceuticals U.S.A., Inc.$217
  • Alkermes, Inc.$147
  • plus $478 from 9 others

What the payments were for

  • Food & beverage$2,35696%
  • Education$1074%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,462 in reported general payments places this provider in the 65th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$6,443
Medicare patients
33
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide15$11,821
Oxcarbazepine18$1,321
Duloxetine Hcl30$987
Hydroxyzine Hcl39$879
Bupropion XlBupropion Hcl35$790
Trazodone Hcl51$740
Escitalopram Oxalate30$562
Aripiprazole18$552
Quetiapine Fumarate18$527
Risperidone11$501
Buspirone Hcl27$494
Doxepin Hcl16$321
Prazosin Hcl16$309
Lamotrigine21$274
Olanzapine14$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$217$11,82115 claims
Almatica Pharma LLCSertraline Hcl$40$6816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →